How Common Is GLP-1 Use for Weight Loss in Saudi Arabia's Eastern Province?

A cross-sectional survey found notable GLP-1 RA use for weight loss among overweight/obese adults in Eastern Saudi Arabia, with specific demographic factors predicting use.

Alhussain, Khalid et al.·Healthcare (Basel·2026·
RPEP-147422026RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

GLP-1 RA use for weight management was prevalent among overweight/obese adults in Eastern Saudi Arabia, with specific demographic and health factors predicting use.

Key Numbers

How They Did This

Cross-sectional survey using an online self-administered questionnaire with chi-square tests and logistic regression analysis.

Why This Research Matters

Understanding real-world patterns of GLP-1 RA use for weight loss helps healthcare systems plan for demand, education needs, and appropriate prescribing oversight.

The Bigger Picture

The global surge in GLP-1 RA use for weight loss, including off-label use, is reshaping obesity treatment patterns in ways that public health systems need to track and manage.

What This Study Doesn't Tell Us

Self-reported survey data subject to recall bias; online questionnaire may not reach all demographic groups; single region limits generalizability.

Questions This Raises

  • ?What proportion of GLP-1 RA weight loss use is off-label vs. prescribed for obesity?
  • ?How do usage patterns in the Eastern Province compare to other Saudi regions?

Trust & Context

Key Stat:
Eastern Province survey Assessing real-world GLP-1 RA weight loss use patterns in Saudi adults
Evidence Grade:
Cross-sectional survey — describes prevalence and associations but cannot establish causation or temporal relationships.
Study Age:
Published 2026. Survey data from December 2024.
Original Title:
Prevalence and Factors Associated with GLP-1 Receptor Agonist Use for Weight Management Among Overweight and Obese Adults in the Eastern Province of Saudi Arabia.
Published In:
Healthcare (Basel, Switzerland), 14(3) (2026)
Database ID:
RPEP-14742

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

Are many people in Saudi Arabia using GLP-1 drugs for weight loss?

This survey found notable prevalence of GLP-1 RA use for weight management among overweight and obese adults in the Eastern Province, reflecting the global trend of increasing use.

What factors predict who uses these medications?

The study identified specific demographic and health-related factors associated with GLP-1 RA use, which can help target education and prescribing efforts.

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-14742·https://rethinkpeptides.com/research/RPEP-14742

APA

Alhussain, Khalid; Alshakhs, Zainab; Albaqshi, Layla; Alshaqaqiq, Fawatim; Alrabiah, Mohammed; Tripathi, Rina. (2026). Prevalence and Factors Associated with GLP-1 Receptor Agonist Use for Weight Management Among Overweight and Obese Adults in the Eastern Province of Saudi Arabia.. Healthcare (Basel, Switzerland), 14(3). https://doi.org/10.3390/healthcare14030345

MLA

Alhussain, Khalid, et al. "Prevalence and Factors Associated with GLP-1 Receptor Agonist Use for Weight Management Among Overweight and Obese Adults in the Eastern Province of Saudi Arabia.." Healthcare (Basel, 2026. https://doi.org/10.3390/healthcare14030345

RethinkPeptides

RethinkPeptides Research Database. "Prevalence and Factors Associated with GLP-1 Receptor Agonis..." RPEP-14742. Retrieved from https://rethinkpeptides.com/research/alhussain-2026-prevalence-and-factors-associated

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.